HomeB1MR34 • BVMF
add
Biomarin Pharmaceutical Inc Bdr
Previous close
R$165.45
Year range
R$165.45 - R$258.34
Market cap
11.37B USD
Avg Volume
47.00
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 745.14M | 14.84% |
Operating expense | 210.96M | -12.17% |
Net income | 185.69M | 109.43% |
Net profit margin | 24.92 | 82.43% |
Earnings per share | 1.13 | 59.15% |
EBITDA | 245.96M | 132.45% |
Effective tax rate | 22.01% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.27B | 21.57% |
Total assets | 7.15B | 3.99% |
Total liabilities | 1.35B | -24.76% |
Total equity | 5.79B | — |
Shares outstanding | 191.78M | — |
Price to book | 5.48 | — |
Return on assets | 7.92% | — |
Return on capital | 8.82% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 185.69M | 109.43% |
Cash from operations | 174.39M | 271.28% |
Cash from investing | -28.24M | -98.36% |
Cash from financing | -38.78M | 9.38% |
Net change in cash | 105.96M | 1,403.17% |
Free cash flow | 102.79M | 376.04% |
About
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Founded
Mar 1997
Headquarters
Website
Employees
3,040
